An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: Analysis and simulation of the Hopkins Lupus Cohort

Rheumatology (United Kingdom)

Volumn 54, Issue 4, 2014, Pages 623-632

  Watson, Penny ^a   Brennan, Alan ^a   Birch, Helen ^b   Fang, Hong ^c   Petri, Michelle ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Health economics; Health outcomes; Statistics; Systemic lupus erythematosus

Indexed keywords

PREDNISONE;

ADULT; AFRICAN AMERICAN; ANEMIA; ARTICLE; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE ACTIVITY; DNA BINDING; DRUG DOSE INCREASE; EYE INJURY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPOGONADISM; KIDNEY INJURY; LONGITUDINAL STUDY; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCULOSKELETAL DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN DEFECT; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84926455293     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu375     Document Type: Article

References (42)

1. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
2. Navarra SV, Guzman RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
3. Brennan A, Akehurst R. Modelling in health economic evaluation. What is its place? What is its value? Pharmacoeconomics 2000;17:445-59.
4. Clarke PM, Gray AM, Briggs A et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59.
5. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol 1995;22:1265-70.
6. Alarcon GS, McGwin G Jr, Bastian HM et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum 2001;45:191-202.
7. Becker-Merok A, Nossent HC. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol 2006;33:1570-7.
8. Cook RJ, Gladman DD, Pericak D, Urowitz MB. Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. J Rheumatol 2000;27:1892-5.
9. Ibanez D, Urowitz MB, Gladman DD. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol 2003;30:1977-82.
10. Alarcon GS, Roseman JM, McGwin G Jr et al. Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology 2004;43: 202-5.
11. Gilboe IM, Kvien TK, Husby G. Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years. J Rheumatol 2001;28:266-74.
12. Ibanez D, Gladman DD, Urowitz MB. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005;32: 824-7.
13. Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 2012;64:4021-8.
14. Thamer M, Hernan MA, Zhang Y, Cotter D, Petri M. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009;36:560-4.
15. Toloza SM, Roseman JM, Alarcon GS et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. Arthritis Rheum 2004;50:3177-86.
16. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-8.
17. Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012;176: 708-19.
18. Latimer N. NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations Alongside ClinicalTrials-Extrapolations with Patient Level data: Report by the Decision Support Unit, 2011. Available at http://www.nicedsu.org.uk.
19. Gladman D, Ginzler E, Goldsmith C et al. Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus. J Rheumatol 1992;19:1820-1.
20. Bertoli AM, Vila LM, Apte M et al. Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: anaemia as a predictor of disease activity and damage accrual. Rheumatology 2007;46:1471-6.
21. Fernandez M, Alarcon GS, Apte M et al. Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor. Arthritis Rheum 2007;56:614-21.
22. Ho A, Magder LS, Barr SG, Petri M. Decreases in antidouble-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2342-9.
23. Ho A, Barr SG, Magder LS, Petri M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2350-7.
24. Zhang J, Gonzalez LA, Roseman JM et al. Predictors of the rate of change in disease activity over time in LUMINA, a multiethnic US cohort of patients with systemic lupus erythematosus: LUMINA LXX. Lupus 2010;19:727-33.
25. Bernatsky S, Peschken C, Fortin PR et al. Medication use in systemic lupus erythematosus. J Rheumatol 2011;38: 271-4.
26. Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology 2012;51:491-8.
27. Fessler BJ, Alarcon GS, McGwin G Jr et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473-80.
28. Bertoli AM, Alarcon GS, Calvo-Alen J et al. Systemic lupus erythematosus in a multiethnic US cohort. XXXIII. Clinical [corrected] features, course, and outcome in patients with late-onset disease. Arthritis Rheum 2006;54:1580-7.
29. Alarcon GS, Roseman JM, McGwin G Jr et al. Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology 2004;43: 202-5.
30. Tan TC, Fang H, Magder LS, Petri MA. Differences between male and female systemic lupus erythematosus in a multiethnic population. J Rheumatol 2012;39:759-69.
31. Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004;164:77-82.
32. Diggle P, Heagerty P, Liang K, Zeger S. Random Effects Models. Analysis of Longitudinal Data. Oxford, UK: Oxford University Press, 2002:169-89.
33. StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp, 2011.
34. Gladman DD, Urowitz MB, Goldsmith CH et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13.
35. Collett D. Modelling Survival Data in Medical Research. 2nd edn. Boca Raton, FL, USA: Chapman & Hall, 2003.
36. Simul8. Simul8 Simulation Software. Boston, MA, USA: Simul8, 2008.
37. Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus-a 5-yr prospective study. Rheumatology 2004;43: 1039-44.
38. Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
39. Nikpour M, Urowitz MB, Ibanez D, Harvey PJ, Gladman DD. Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. Arthritis Res Ther 2011;13:R156.
40. Furie RA, Petri MA, Wallace DJ et al. Novel evidencebased systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51.
41. Touma Z, Gladman DD, Ibanez D et al. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials. J Rheumatol 2011;38: 2395-9.
42. Urowitz MB, Gladman DD, Ibanez D et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res 2012;64:132-7.